Dear Ms. Burns:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 18, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Voltaren Gel (diclofenac sodium topical gel), 1%.

We acknowledge receipt of your amendment(s) dated August 16, 2012, December 20, 2013, and June 17, 2014.

This “Changes Being Effected” supplemental new drug application provides for changes to product labeling, including the prescribing information, instructions for use, and carton and container labeling, intended to alert the consumer to look for the dosing card inside the carton, and utilize the dosing card to properly administer an accurate dose of the topical gel.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide, and Instructions for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Reference ID: 3664042
Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**CARTON AND IMMEDIATE CONTAINER LABELS**

We acknowledge your December 20, 2013, submission containing final printed carton and container labels.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Dominic Chiapperino, PhD, Senior Regulatory Health Project Manager, at (301) 796-1183.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, MD
Acting Director
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON H HERTZ
11/25/2014